Ten-Year, Thirty-Year, and Lifetime Cardiovascular Disease Risk Estimates Following a Pregnancy Complicated by Preeclampsia

Journal of Obstetrics and Gynaecology Canada

Volumn 34, Issue 9, 2012, Pages 830-835

  Smith, Graeme N ^a   Pudwell, Jessica ^a   Walker, Mark ^b   Wen, Shi Wu ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Cardiovascular disease; Cardiovascular risk; Preeclampsia; Pregnancy; Risk estimates

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LONGITUDINAL STUDY; MATERNAL SMOKING; PREECLAMPSIA; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; PATHOPHYSIOLOGY; PREGNANCY; SMOKING;

ADULT; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIPIDS; LONGITUDINAL STUDIES; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84876174785     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)35381-6     Document Type: Article

References (18)

1. Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynecol 2003, 15:465-471.
2. Smith G.N. The development of pre-eclampsia provides a window of opportunity for early cardiovascular risk screening and intervention. Expert Rev Obstet Gynecol 2009, 4:355-357.
3. Smith G.N., Walker M., Liu A., Wen S.W., Swansburg M., Ramshaw H., et al. A history of preeclampsia identifies women who have underlying cardiovascular risk factors. Am J Obstet Gynecol 2009, 200:58.
4. Smith G.C.S., Pell J.P., Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001, 357:2002-2006.
5. Retnakaran R. Glucose tolerance status in pregnancy: a window to the future risk of diabetes and cardiovascular disease in young women. Curr Diabetes Rev 2009, 5:239-244.
6. Retnakaran R., Shah B.R. Mild glucose intolerance in pregnancy and risk of cardiovascular disease: a population-based cohort study. CMAJ 2009, 181:371-376.
7. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005, 366:1797-1803.
8. Irgens H.U., Reisaeter L., Lie R.T. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001, 323:1213-1217.
9. Mosca L., Benjamin E.J., Berra K., Bezanson J.L., Dolor R.J., Lloyd-Jones D., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update. J Am Coll Cardiol 2011, 57:1404-1423.
10. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M.R., Massaro J.M., et al. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 2008, 117:743-753.
11. Pencina M.J., D'Agostino R.B., Larson M.G., Massaro J.M., Vasan R.S. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation 2009, 119:3078-3084.
12. Lloyd-Jones D., Leip E.P., Larson M.G., D'Agostino R.B., Beiser A.S., Wilson P.W., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
13. Ridker P.M., Macfadyen J.G., Nordestgaard B.G., Koenig W., Kastelein J.J., Genest J., et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes 2010, 3:447-452.
14. Lloyd-Jones D. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. Curr Opin Lipidol 2006, 17:619-625.
15. Ridker P.M., Buring J.E., Rifai N. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women:The Reynolds Risk Score. JAMA 2007, 297:611-619.
16. Hermes W., Franx A., van Pampus M.G., Bloemenkamp K.W., van der Post J.A., Porath M., et al. 10-year cardiovascular event risks for women who experienced hypertensive disorders in late pregnancy: the HyRAS study. BMC Pregnancy Childbirth 2010, 10:28.
17. Fraser A., Nelson S.M., Macdonald-Wallis C., Cherry L., Butler E., Sattar N., et al. Association of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: The Avon Longitudinal Study of Parents and Children. Circulation 2012, 125:1367-1380.
18. Smith E.R. Canadian heart health strategy and action plan (CHHS-AP) 2010, Available at, Accessed July 5, 2011. http://www.chhs.ca.